Suppr超能文献

脂质体:从奥古斯特·瓦塞尔曼到抗新冠病毒疫苗

Liposomes: from August Wassermann to vaccines against COVID-19.

作者信息

Grygorieva Ganna, Pylypenko Daria, Krasnopolsky Yuriy

机构信息

SI "Institute of Pharmacology and Toxicology of NAMS of Ukraine", 14, Ezhene Potier Str., Kyiv, 03680, Ukraine.

State Biotechnological University, 44, Alchevskikh str., Kharkiv, 61002, Ukraine.

出版信息

ADMET DMPK. 2023 Jun 30;11(4):487-497. doi: 10.5599/admet.1926. eCollection 2023.

Abstract

BACKGROUND AND PURPOSE

The development of vaccines against the SARS-CoV-2 virus has become a big challenge for many countries in 2020-2022. mRNA vaccines were shown to be effective and safe and have been widely used worldwide in the fight against the COVID-19 pandemic. The fundamental factor in creating mRNA vaccines, which ensures effective delivery of mRNA to the host cells, is the composition of lipid nanoparticles, namely the presence of ionized charged lipids, which ensures the binding of mRNA molecules. However, the significant role of liposomes in the development of liposomal vaccines and identification of immunochemical reactions involving lipids should be assessed in the context of the development of the pioneering idea of August Wassermann about the use of liposomal antigens in the diagnosis and immunoprophylaxis of serious human diseases.

EXPERIMENTAL APPROACH

The review is devoted to the use of liposomal antigens as antigen-delivery systems for diagnosis and immunoprophylaxis.

KEY RESULTS

Studies of cardiolipin antigen in serodiagnosis of syphilis became the foundation of antibodies in diagnosing various infectious diseases and pathological conditions, such as tuberculosis, lupus erythematosus, COVID-19, borreliosis, etc. Identification of antiphospholipid antibodies (mainly anticardiolipin) and today is the most important diagnostic tool for antiphospholipid syndrome.

CONCLUSION

The liposomal system first proposed in 1906 for the diagnosis of syphilis evolved more than a century later into mRNA vaccines, which are used today in the fight against the COVID-19 pandemic.

摘要

背景与目的

在2020 - 2022年期间,研发针对严重急性呼吸综合征冠状病毒2(SARS-CoV-2)的疫苗对许多国家而言已成为一项重大挑战。信使核糖核酸(mRNA)疫苗已被证明有效且安全,并在全球范围内广泛用于抗击2019冠状病毒病(COVID-19)大流行。制造mRNA疫苗的一个基本因素是脂质纳米颗粒的组成,即电离带电脂质的存在,这确保了mRNA分子的结合,从而保证mRNA有效地递送至宿主细胞。然而,在奥古斯特·瓦塞尔曼关于使用脂质体抗原诊断和免疫预防严重人类疾病这一开创性理念的发展背景下,应评估脂质体在脂质体疫苗研发以及涉及脂质的免疫化学反应鉴定中的重要作用。

实验方法

本综述致力于脂质体抗原作为诊断和免疫预防的抗原递送系统的应用。

关键结果

心磷脂抗原在梅毒血清学诊断中的研究成为诊断各种传染病和病理状况(如结核病、红斑狼疮、COVID-19、莱姆病等)中抗体检测的基础。抗磷脂抗体(主要是抗心磷脂抗体)的鉴定如今是抗磷脂综合征最重要的诊断工具。

结论

1906年首次提出用于梅毒诊断的脂质体系统在一个多世纪后演变成了mRNA疫苗,如今用于抗击COVID-19大流行。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9ccd/10626513/9efc74955475/ADMET-11-1926-g001.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验